Currently, the most common forms of chronic inflammatory bowel disease are nonspecific ulcerative colitis and Crohn’s disease, which affect various parts of the gastrointestinal tract. These pathological disorders are considered to be idiopathic inflammatory diseases of the gastrointestinal tract resulting from the combined effects of environmental factors, social conditions, qualitative and quantitative changes in the composition of the intestinal microbiota, and immune factors. Modern research has identified the interrelations of the metabolism of epithelial cells in the intestinal mucosa and representatives of the microbiota with the body’s immune response through communication and regulation pathways, which allows the body to function properly. Understanding cross-regulatory pathways provides a basis for identifying therapeutic targets that can be influenced by metabolic modulation to inhibit inflammation in inflammatory bowel diseases.

Ключові слова: ulcerative colitis, inflammatory bowel disease, immune response, microbiota

Повний текст: PDF (Ukr)

1. Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023; 165: 1197–1205.e2. doi.org/10.1053/j.gastro.2023.07.0035
2. Наказ МОЗ України від 6 жовтня 2023 р. № 1742: Уніфікований клінічний протокол первинної та спеціалізованої медичної допомоги запальні захворювання кишечника (хвороба Крона, виразковий коліт). dec.gov.ua/wp-content/uploads/2023/10/ukpmd_1742_06102023.pdf
3. Barna OM, Odynets MО. Inflammatory bowel diseases and modern methods of their treatment. Medicine of Ukraine. 2024;3(279):28-30. doi.org/10.37987/1997-9894.2024.3(279).306579
4. Samant SA, Hyoju SK, Alverdy JC, Gupta MP . The multifaceted role of sirtuins in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2025; 329:G58–G68. doi.org/10.1152/ajpgi.00311.2024
5. Vieujean S, Caron B, Jairath V, Benetos A, Danese S, Louis E, et al. Is it time to include older adults in inflammatory bowel disease trials? A call for action. Lancet Healthy Longev. 2022;3:e356–e366. doi.org/10.1016/S2666-7568(22)00060-5
6. Kalla R, Ventham NT, Kennedy NA, Quintana JF, Nimmo ER, Buck AH, et al. MicroRNAs:new players in IBD. Gut. 2015;64:504–17. doi.org/10.1136/gutjnl-2014-307891
7. Ishfaq Ah., Badal C. R., Salman A. Kh., Septer S., Shahid U. Microbiome, Metabolome and Inflammatory Bowel Disease. Microorganisms. 2016;4(20):19. doi.org/10.3390/microorganisms4020020
8. Радченко ОМ. Сучасні підходи до діагностики та лікування запальних хвороб товстої кишки в практиці лікаря загальної практики. Здоров’я України. 2021;8(501):53-7. health-ua.com
9. Schaubeck M, Clavel T, Calasan J, Lagkouvardos I, Haange SB, Jehmlich N, et al. Dysbiotic Gut Microbiota Causes Transmissible Crohn’s Disease- Like Ileitis Independent of Failure in Antimicrobial Defence. Gut. 2016;65(2):225–37.doi.org/10.1136/gutjnl-2015-309333
10. Momozawa Y, Dmitrieva J, Théâtre E, Deffontaine V, Rahmouni S, Charloteaux B, et al. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat Commun. 2018; 9: 2427.doi.org/10.1038/s41467-018-04365-8
11. Kayama H, Okumura R, Takeda K. Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine. Annu. Rev. Immunol. 2020.38:23–48. doi.org/10.1146/annurev-immunol-070119-115104
12. Shkoporov AN, Hill C. Bacteriophages of the human gut: the «known unknown» of the microbiome. Cell Host Microbe. 2019; 25: 195–209.doi.org/10.1016/j.chom.2019.01.017
13. Michaudel C, Sokol H. The Gut Microbiota at the Service of Immunometabolism. Cell Metabolism. 2020;32(6):514-23. doi.org/10.1016/j.cmet.2020.09.004
14. Morshedi M, SaghafiAsl M, Hosseinifard ES. The potential therapeutic effects of the gut microbiome manipulation by synbiotic containing Lactobacillus plantarum on neuropsychological performance of diabetic rats. J. Transl. Med. 2020;18(1):18.doi.org/10.1186/s12967-019-02169-y
15. Bati V.V. Bugyna L.M. Koval G.M. The impact of the gut microbiome on human psychological state. Ukrainian Medical Journal. 2022;4(150);VII/VIII:1-4. doi.org/10.32471/umj.1680-3051.150.232948
16. Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The Gut Microbiota in Inflammatory Bowel Disease. Front. Cell. Infect. Microbiol. 2022;12:733992. doi.org/10.3389/fcimb.2022.733992
17. Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, et al. Gut Microbiota Composition and Functional Changes in Inflammatory Bowel Disease and Irritable Bowel Syndrome. Sci. Transl. Med. 2018;10(472):eaap8914. doi.org/10.1126/scitranslmed.aap8914
18. Pittayanon R, Lau JT, Leontiadis GI, Tse F, Yuan Y, Surette M, et al. Differences in Gut Microbiota in Patients with vs Without Inflammatory Bowel Diseases: A Systematic eview.Gastroenterology. 2020;158,4:930–946.e931. doi.org/10.1053/j.gastro.2019.11.294
19. Birimberg-Schwartz L, Wilson DC, Kolho KL, Karolewska-Bochenek K, Afzal NA, Spray C, et al. pANCA and ASCA in Children with IBD-Unclassified, Crohn’s Colitis, and Ulcerative Colitis-A Longitudinal Report from the IBD Porto Group of ESPGHAN. Inflamm Bowel Dis.2016;22(8):1908-14.doi.org/10.1097/MIB.0000000000000784
20. Andersen V, Chan S, Luben R, Khaw KT, Olsen A, Tjonneland A, et al. Fibre intake and the development of inflammatory bowel disease: A European prospective multicentre cohort study (EPIC-IBD). Journal of Crohn’s and Colitis. 2018;12(2):129-36.doi.org/10.1093/ecco-jcc/jjx136
21. Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 2018;67(3):574-87. doi.org/10.1136/gutjnl-2017-314903
22. Bobrova V. І. The role of NF-kB in the mechanisms of inflammation of the stomach’s mucosa in children. Modern Pediatrics. Ukraine. 2023;4(132):23-7.doi.org/10.15574/SP.2023.132.23
23. Zhang S, Paul S, Kundu P. NF-κB Regulation by Gut Microbiota Decides Homeostasis or Disease Outcome During Ageing. Front. Cell Dev. Biol. 2022;10:874940. doi.org/10.3389/fcell.2022.874940
24. Pandey H, Jain D, Tang DWT, Wong SH, Lal D. Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease. Intest Res. 2024;22(1):15-43. doi.org/10.5217/ir.2023.00080
25. Anderson CJ, Medina CB, Barron BJ, Karvelyte L, et al. Microbes exploit death-induced nutrient release by gut epithelial cells. 2021;596(7871):262-67.doi.org/10.1038/s41586-021-03785-9
26. Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223-37.doi.org/10.1038/s41575-019-0258-z
27. Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR, Ng R, et al. Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice. Immunity. 2019;15;50(1):212-24. e4.doi.org/10.1016/j.immuni.2018.12.015
28. Leber A, Hontecillas R, Tubau-Juni N, Zoccoli-Rodriguez V, Abedi V, et al. NLRX1 Modulates Immunometabolic Mechanisms Controlling the Host-Gut Microbiota Interactions during Inflammatory Bowel Disease. Front Immunol. 2018;26:9:363. doi.org/10.3389/fimmu.2018.00363
29. Kayama H, Okumura R, Takeda K. Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine. Annu. Rev. Immunol. 2020; 38: 23-48.doi.org/10.1146/annurev-immunol-070119-115104
30. Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, et al. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potentia Therapeutic Strategies. Front Med (Lausanne). 2021;13:8:766126.doi.org/10.3389/fmed.2021.766126
31. Wang M, Fu R, Xu D, Chen Y, Yue S, Zhang S, et al. Traditional Chinese Medicine: A promising strategy to regulate the imbalance of bacterial flora, impaired intestinal barrier and immune function attributed to ulcerative colitis through intestinal microecology. Ethnopharmacol. 2024; 10;318(Pt A):116879. doi.org/10.1016/j.jep.2023.116879
32. Hu S, Uniken Venema WT, Westra HJ, Vich Vila A, Barbieri R, Voskuil MD, et al. Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease. Nat Commun. 2021;12:1122.doi.org/10.1038/s41467-021-21458-z
33. Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine. 2021;66:103293. doi.org/10.1016/j.ebiom.2021.103293
34. Jaric I, Voelkl B, Clerc M, Schmid MW, Novak J, Rosso M, et al. The rearing environment persistently modulates mouse phenotypes from the molecular to the behavioural level. 2022;20(10):e3001837.doi.org/10.1371/journal.pbio.3001837
35. Yan L, Wang J, Cai X, Liou YC, Shen HM, Hao J, et al. Macrophage plasticity: signaling pathways, tissue repair, and regeneration. MedComm. 2024;5:e658:42 p. doi.org/10.1002/mco2.658
36. Rolot M, O’Sullivan TO. Living with Yourself: Innate Lymphoid Cell Immunometabolism.Cells. 2020; 9:334.doi.org/10.3390/cells 11162555
37. Wen Y, Wang H, Tian D, Wang G. TH17 cell: a double-edged sword in the development of inflammatory bowel disease. Ther Adv Gastroenterol. 2024; 17: 1–20. doi.org/10.1177/17562848241230896
38. Calvez V, Puca P, Di Vincenzo F, Del Gaudio A, Bartocci B, Murgiano M, et al. Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases. Biomedicines. 2025,13(2):305.doi.org/10.3390/biomedicines13020305
39. Powell N, Pantazi E, Pavlidis P, Tsakmaki A, Li K, Yang F, et al. Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. Gut. 2020; 69(3): 578-90. doi.org/10.1136/gutjnl-2019-318483
40. Cosovanu C, Neumann C. The Many Functions of Foxp3+ Regulatory T Cells in the Intestine. Front Immunol. 2020;11:600973.doi.org/10.3389/fimmu.2020.600973
41. Mickael ME, Suniti Bhaumik S, Basu R. Retinoid-Related Orphan Receptor RORgt in CD4D T-CelleMediated Intestinal Homeostasis and Inflammation Am J Pathol 2020;190:1984e1999.doi.org/10.1016/j.ajpath.2020.07.010
42. Zhao D, Ge A, Yan C, Liu X, Yang K, Yan Y, et al. T helper cell 17/regulatory T cell balance regulates ulcerative colitis and the therapeutic role of natural plant components: a review. Front Med (Lausanne). 2025;11:1502849.doi.org/10.3389/fmed.2024.1502849
43. Saleh MM, Frisbee AL, Leslie JL, Buonomo EL, Cowardin CA, Ma JZ, et al. Colitis-induced Th17 cells increase the risk for severe subsequent Clostridium difficile infection. Cell Host Microbe. 2019;25(5):756–65.doi.org/10.1016/j.chom.2019.03.003
44. Roustapoor R, Abdi E, Khabbaz A, Abdi A. The metabolic and immunomodulatory functions of Bacteroides fragilis; a next-generation probiotic? Medicine in Microecology. 2025;25: 100137. doi.org/10.1016/j.medmic.2025.100137
45. Li K, Hao Z, Du J, Gao Y, Yang S, Zhou Y. Bacteroides thetaiotaomicron relieves colon inflammation by activating aryl hydrocarbon receptor and modulating CD4+T cell homeostasis. International immunopharmacology. 2021; 90: 107183. doi.org/10.1016/j.intimp.2020.107183
46. Chiang MK, Hsiao PY, Liu YY, Tang HL, Chiou CS, Lu MC, et al. Two ST11 Klebsiella pneumoniae strains exacerbate colorectal tumorigenesis in a colitis-associated mouse model.Gut Microbes. 2021;13(1):1980348. doi.org/10.1080/19490976.2021.1980348